6-K
GSK plc (GSK)
6-K
2026-03-23
For: 2026-03-23
View Original
Added on
April 10, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2026
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||
|---|---|---|---|
| a) | Name | Sir Jonathan Symonds | |
| b) | Position/status | Non-Executive Chair | |
| c) | Initial<br>notification/amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||
| a) | Name | GSK plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |
| b) | Nature<br>of the transaction | Purchase of 5,000 Ordinary Shares | |
| c) | Price(s)<br>and volume(s) | Volume(s) | |
| 2,500 | |||
| 2,500 | |||
| d) | Aggregated<br>information | ||
| Aggregated volume Price | 5000 Ordinary Shares<br><br><br>19.5111 | ||
| e) | Date<br>of the transaction | 2026-03-20 | |
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Wendy Becker | ||
| b) | Position/status | Independent Non-Executive Director | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Purchase of 411 Ordinary Shares | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £19.6250 | 411 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2026-03-20 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Elizabeth (Liz) McKee Anderson | ||
| b) | Position/status | Independent Non-Executive Director | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADS')<br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Purchase of 196 ADS | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $51.7939 | 196 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2026-03-20 | ||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Charles Bancroft | ||
| b) | Position/status | Senior Independent Non-Executive Director | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADS')<br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Purchase of 1,536 ADS | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $51.7939 | 1,536 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2026-03-20 | ||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dr Anne Beal | ||
| b) | Position/status | Independent Non-Executive Director | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADS')<br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Purchase of 196 ADS | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $51.7939 | 196 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2026-03-20 | ||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dr Hal Dietz | ||
| b) | Position/status | Independent Non-Executive Director | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADS')<br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Purchase of 196 ADS | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $51.7939 | 196 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2026-03-20 | ||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dr Jeannie Lee | ||
| b) | Position/status | Independent Non-Executive Director | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADS')<br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Purchase of 195 ADS | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $51.7939 | 195 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2026-03-20 | ||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dr Gavin Screaton | ||
| b) | Position/status | Independent Non-Executive Director | ||
| c) | Initial notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market<br>participant, auction platform, auctioneer or auction<br>monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated<br>for (i) each type of instrument; (ii) each type of transaction;<br>(iii) each date; and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature of the transaction | Purchase of 6,335 Ordinary Shares | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| £19.6294 | 6,335 | |||
| d) | Aggregated information | N/A (single transaction) | ||
| Aggregated volume Price | ||||
| e) | Date of the transaction | 2026-03-18 | ||
| f) | Place of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dr Vishal Sikka | ||
| b) | Position/status | Independent Non-Executive Director | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADS')<br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Purchase of 797 ADS | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $51.7939 | 797 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2026-03-20 | ||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) |
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
|---|---|
| (Registrant) | |
| Date: March<br>23, 2026 | |
| By:/s/ VICTORIA<br>WHYTE<br><br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GSK plc |